Sulfapyridine

Sulfapyridine

SCHEMBL44219

Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfapyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 1.00
KDM4E B2RXH2 8/20 0.71
LMNA P02545 5/20 0.71
AURKA O14965 1/20 0.68
DHFR P00374 1/20 0.68
TSHR P16473 1/20 0.68
POLB P06746 1/20 0.68
ALDH1A1 P00352 2/20 0.66
HSD11B1 P28845 1/20 0.61
ALPL P05186 1/20 0.60
GAA P10253 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP2C9 P11712 1/20 0.60
MAPK1 P28482 2/20 0.59
HSD17B10 Q99714 1/20 0.59
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
PRMT1 Q99873 1/20 0.57
BRD4 O60885 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfapyridine SCHEMBL29438089 1.00 SMN1; SMN2 (1.00) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL668918 0.98 SMN1; SMN2 (0.97) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL11706483 0.98 SMN1; SMN2 (0.97) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL3714634 0.98 SMN1; SMN2 (0.97) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL27741790 0.98 SMN1; SMN2 (0.97) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL27974729 0.97 SMN1; SMN2 (0.94) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL668917 0.97 SMN1; SMN2 (0.94) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL11778484 0.95 SMN1; SMN2 (0.91) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL28142861 0.94 SMN1; SMN2 (0.88) SMN1; SMN2KDM4ELMNAAURKADHFR
Sulfapyridine SCHEMBL2243590 0.89 SMN1; SMN2 (0.79) SMN1; SMN2KDM4ELMNAAURKADHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7447 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260117393-A1 ETCHING AGENT COMPOSITION AND ETCHING METHOD USING THE SAME KCTECH CO., LTD. (KR) 2026-04-30 US claimed
EP-4724049-A1 MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF Catalent Ontario Limited (CA) 2026-04-15 EP claimed
CN-120195301-A Method and system for detecting various antibiotics in water based on artificial intelligence 广东中加检测技术股份有限公司 2025-06-24 CN claimed
CN-118465149-B Pretreatment method for improving analysis efficiency of various antibiotics in organic fertilizer 生态环境部南京环境科学研究所 2025-06-13 CN claimed
CN-116890109-B Preparation method of flexible Raman detection substrate and application of flexible Raman detection substrate in rapid detection of drug residues in water 广东省科学院测试分析研究所(中国广州分析测试中心) 2025-06-03 CN claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
CN-120025007-A Application of constructed wetland in removal of sulfonamide antibiotics and resistance genes in water body 海南热带海洋学院 2025-05-23 CN claimed
CN-120022878-A Amphiphilic covalent organic framework mixed mode chromatographic stationary phase and preparation method and application thereof 河南工业大学 2025-05-23 CN claimed
EP-4552661-A2 MEDICAL DEVICES HAVING ANTI-MICROBIAL PROPERTIES AND METHODS FOR MAKING THE SAME Hollister Incorporated (US) 2025-05-14 EP claimed
EP-4178637-B1 MEDICAL DEVICES HAVING ANTI-MICROBIAL PROPERTIES AND METHODS FOR MAKING THE SAME HOLLISTER INC (US) 2025-05-14 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
US-5208150-A Adding 7-ethyl-2-methyl-4-undecanol hydrogen sulfate and salts to suppress Salmonella THE UNIVERSITY OF MARYLAND (US) 1993-05-04 US claimed
WO-1992017607-A1 SALMONELLA-SELECTIVE PLATING MEDIUM UNIVERSITY OF MARYLAND COLLEGE PARK (US) 1992-10-15 WO claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
US-4725355-A SULFA DRUG ON SUPPORT TERUMO KABUSHIKI KAISHA (JP) 1988-02-16 US claimed
US-4599416-A Process for the preparation of aqueous solutions of potentiated sulfonamides HOFFMANN-LA ROCHE INC. (US) 1986-07-08 US claimed
US-4532245-A Pharmaceutical compositions HOFFMANN-LA ROCHE INC. (US) 1985-07-30 US claimed
US-4315931-A MICROBIOCIDES, INFECTIOUS DISEASES BASF AKTIENGESELLSCHAFT (DE) 1982-02-16 US claimed
US-4122158-A FOR TREATMENT OF BURNS; BIODEGRADABLE HYDROPHOBIC POLYMER; SUSTAINED RELEASE ALZA CORPORATION (US) 1978-10-24 US claimed
US-3983209-A HYDROPHOBIC BIOERODIBLE POLYMER, MICROBIOCIDE OR PROTEOLYTIC ENZYME ALZA CORPORATION (US) 1976-09-28 US claimed